SG11201403106SA - Anti-phf-tau antibodies and their uses - Google Patents
Anti-phf-tau antibodies and their usesInfo
- Publication number
- SG11201403106SA SG11201403106SA SG11201403106SA SG11201403106SA SG11201403106SA SG 11201403106S A SG11201403106S A SG 11201403106SA SG 11201403106S A SG11201403106S A SG 11201403106SA SG 11201403106S A SG11201403106S A SG 11201403106SA SG 11201403106S A SG11201403106S A SG 11201403106SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pennsylvania
- rule
- king
- johnson
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 June 2013 (27.06.2013) WIPOIPCT (10) International Publication Number WO 2013/096380 A3 (51) International Patent Classification: C07K16/00 (2006.01) A61K39/00 (2006.01) (21) International Application Number: PCT/US2012/070486 19 December 2012 (19.12.2012) (22) International Filing Date: 1 (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 61/577,817 20 December 2011 (20.12.2011) US (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US). (72) Inventors: ALDERFER, Christopher; 145 King of Prus sia Road, Radnor, Pennsylvania 19087 (US). JANECKI, Dariusz; 145 King of Prussia Road, Radnor, Pennsylvania 19087 (US). LU, Xuesong; 145 King of Prussia Road, — Radnor, Pennsylvania 19087 (US). MURDOCK, Melissa; 145 King of Prussia Road, Radnor, Pennsylvania 19087 (US). WU, Sheng-Jiun; 145 King of Prussia Road, Rad nor, Pennsylvania 19087 (US). MERCKEN, Marc; Turnhoutseweg 30, B-2340 Beerse (BE). VANDER- MEEREN, Marc; Turnhoutseweg 30, B-2340 Beerse (BE). (74) Agents: JOHNSON, Philip S. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jer sey 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the identity of the inventor (Rule 4.17(i)) as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 22 August 2013 o 00 m o\ © en i-H o CJ 0 (54) Title: ANTI-PHF-TAU ANTIBODIES AND THEIR USES ^ (57) Abstract: Anti-PHF-tau antibodies and methods of and making using them are disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161577817P | 2011-12-20 | 2011-12-20 | |
PCT/US2012/070486 WO2013096380A2 (en) | 2011-12-20 | 2012-12-19 | Anti-phf-tau antibodies and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201403106SA true SG11201403106SA (en) | 2014-12-30 |
Family
ID=48669693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201403106SA SG11201403106SA (en) | 2011-12-20 | 2012-12-19 | Anti-phf-tau antibodies and their uses |
Country Status (34)
Country | Link |
---|---|
US (4) | US9371376B2 (en) |
EP (2) | EP2794654B1 (en) |
JP (4) | JP6306513B2 (en) |
KR (1) | KR101991681B1 (en) |
CN (2) | CN104024274B (en) |
AU (2) | AU2012359039B2 (en) |
BR (1) | BR112014015323B1 (en) |
CA (2) | CA3234629A1 (en) |
CO (1) | CO6980627A2 (en) |
CY (1) | CY1121862T1 (en) |
DK (1) | DK2794654T3 (en) |
EA (1) | EA027975B1 (en) |
EC (1) | ECSP14005975A (en) |
ES (1) | ES2738007T3 (en) |
GT (1) | GT201400127A (en) |
HK (2) | HK1203520A1 (en) |
HR (1) | HRP20191342T1 (en) |
HU (1) | HUE045656T2 (en) |
IL (3) | IL233051B (en) |
LT (1) | LT2794654T (en) |
MX (1) | MX350311B (en) |
MY (2) | MY186066A (en) |
NI (1) | NI201400061A (en) |
NZ (1) | NZ626269A (en) |
PH (1) | PH12014501427B1 (en) |
PL (1) | PL2794654T3 (en) |
PT (1) | PT2794654T (en) |
RS (1) | RS59024B1 (en) |
SG (1) | SG11201403106SA (en) |
SI (1) | SI2794654T1 (en) |
TR (1) | TR201910720T4 (en) |
UA (1) | UA114902C2 (en) |
WO (1) | WO2013096380A2 (en) |
ZA (1) | ZA201405317B (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014015323B1 (en) * | 2011-12-20 | 2022-09-27 | Janssen Biotech, Inc | ANTI-PHF-TAU ANTIBODIES, ITS PRODUCTION METHOD, ISOLATED POLYNUCLEOTIDE ENCODING AN ANTIBODY VH, AND VECTOR |
EP3838921A3 (en) | 2012-07-03 | 2021-09-01 | Washington University | Antibodies to tau |
HUE048780T2 (en) | 2012-08-16 | 2020-09-28 | Ipierian Inc | Methods of treating a tauopathy |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
CN105939722A (en) | 2014-02-14 | 2016-09-14 | 伊皮埃里安股份有限公司 | Tau peptides, anti-tau antibodies, and methods of use thereof |
ZA201608812B (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
EP3160999B1 (en) * | 2014-06-26 | 2018-11-28 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
TW202136296A (en) | 2014-06-27 | 2021-10-01 | 美商C2N醫療診斷有限責任公司 | Humanized anti-tau antibodies |
WO2016112078A2 (en) * | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
TWI669314B (en) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | Antibodies to tau and uses thereof |
TWI790642B (en) | 2015-06-05 | 2023-01-21 | 美商建南德克公司 | Anti-tau antibodies and methods of use |
EA036821B1 (en) | 2015-07-06 | 2020-12-23 | Юсб Биофарма Срл | Tau-binding antibodies |
SG10202010735PA (en) * | 2015-07-06 | 2020-11-27 | UCB Biopharma SRL | Tau-binding antibodies |
WO2017189963A1 (en) * | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
CA3032692A1 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination antibody therapy for the treatment of neurodegenerative diseases |
CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
TW202328181A (en) | 2016-12-07 | 2023-07-16 | 美商建南德克公司 | Anti-tau antibodies and methods of use |
MX2019009817A (en) | 2017-02-17 | 2019-11-21 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof. |
JOP20180014A1 (en) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
JOP20180021A1 (en) * | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | Anti-phf-tau antibodies and uses thereof |
CN111630064B (en) | 2017-10-16 | 2023-06-27 | 卫材R&D管理有限公司 | anti-Tau antibodies and uses thereof |
EP3762414A4 (en) * | 2018-03-05 | 2022-01-05 | Janssen Pharmaceutica NV | Assays to detect neurodegeneration |
AU2019232631A1 (en) * | 2018-03-05 | 2020-09-24 | Janssen Pharmaceutica Nv | Anti-PHF-tau antibodies and uses thereof |
EP3774887A2 (en) * | 2018-03-28 | 2021-02-17 | Axon Neuroscience SE | Antibody-based methods of detecting and treating alzheimer's disease |
JP2021530552A (en) | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | Combination therapy |
WO2021205359A1 (en) * | 2020-04-08 | 2021-10-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and uses thereof |
CN116249712A (en) | 2020-04-15 | 2023-06-09 | 沃雅戈治疗公司 | TAU binding compounds |
JP7554292B2 (en) | 2020-06-25 | 2024-09-19 | メルク・シャープ・アンド・ドーム・エルエルシー | A high affinity antibody targeting tau phosphorylated at serine 413 |
JP2023554382A (en) | 2020-12-16 | 2023-12-27 | ボイジャー セラピューティクス インコーポレイテッド | tau binding compounds |
EP4314048A1 (en) * | 2021-03-26 | 2024-02-07 | Janssen Biotech, Inc. | Anti-tau antibodies and uses thereof |
MX2023011340A (en) * | 2021-03-26 | 2023-12-14 | Janssen Biotech Inc | Humanized antibodies against paired helical filament tau and uses thereof. |
WO2023250388A1 (en) | 2022-06-22 | 2023-12-28 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1993008302A1 (en) | 1991-10-25 | 1993-04-29 | Itt Automotive Europe Gmbh | Monoclonal antibodies directed against the microtubule-associated protein tau |
WO1995017429A1 (en) * | 1993-12-21 | 1995-06-29 | Innogenetics N.V. | Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications |
US6121003A (en) | 1994-07-29 | 2000-09-19 | Innogentics N.V. | Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use |
EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
EP1697741A4 (en) | 2003-12-04 | 2008-02-13 | Xencor Inc | Methods of generating variant proteins with increased host string content and compositions thereof |
US20070048785A1 (en) * | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
JP5406027B2 (en) * | 2006-08-04 | 2014-02-05 | ノバルティス アーゲー | EphB3-specific antibodies and uses thereof |
JP2010235447A (en) * | 2007-07-30 | 2010-10-21 | Igaku Seibutsugaku Kenkyusho:Kk | Inhibitory agent for inflammatory cytokine |
WO2010045340A1 (en) | 2008-10-14 | 2010-04-22 | Centocor Ortho Biotech Inc. | Methods of humanizing and affinity-maturing antibodies |
US9968574B2 (en) * | 2009-05-15 | 2018-05-15 | The University Of Kentucky Research Foundation | Treatment of MCI and Alzheimer's disease |
JP5917394B2 (en) | 2009-06-10 | 2016-05-11 | ニューヨーク・ユニバーシティ | Immunological targeting method of pathological tau protein |
US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
US8912355B2 (en) * | 2009-09-29 | 2014-12-16 | University Of Ottawa Heart Institute | Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes |
DK2488867T3 (en) | 2009-10-14 | 2020-11-09 | Janssen Biotech Inc | PROCEDURES FOR AFFINITY MATURE OF ANTIBODIES |
WO2012045882A2 (en) | 2010-10-07 | 2012-04-12 | Ac Immune S.A. | Pharmaceutical composition |
EP2627672B1 (en) * | 2010-10-11 | 2018-08-01 | Biogen Idec International Neuroscience GmbH | Human anti-tau antibodies |
BR112014015323B1 (en) * | 2011-12-20 | 2022-09-27 | Janssen Biotech, Inc | ANTI-PHF-TAU ANTIBODIES, ITS PRODUCTION METHOD, ISOLATED POLYNUCLEOTIDE ENCODING AN ANTIBODY VH, AND VECTOR |
-
2012
- 2012-12-19 BR BR112014015323-0A patent/BR112014015323B1/en active IP Right Grant
- 2012-12-19 EA EA201491224A patent/EA027975B1/en not_active IP Right Cessation
- 2012-12-19 ES ES12859920T patent/ES2738007T3/en active Active
- 2012-12-19 WO PCT/US2012/070486 patent/WO2013096380A2/en active Application Filing
- 2012-12-19 CN CN201280062971.8A patent/CN104024274B/en active Active
- 2012-12-19 NZ NZ626269A patent/NZ626269A/en unknown
- 2012-12-19 CN CN201710472573.8A patent/CN107226863B/en active Active
- 2012-12-19 MX MX2014007476A patent/MX350311B/en active IP Right Grant
- 2012-12-19 KR KR1020147019911A patent/KR101991681B1/en active IP Right Grant
- 2012-12-19 MY MYPI2017000364A patent/MY186066A/en unknown
- 2012-12-19 MY MYPI2014701643A patent/MY178142A/en unknown
- 2012-12-19 US US14/363,888 patent/US9371376B2/en active Active
- 2012-12-19 LT LT12859920T patent/LT2794654T/en unknown
- 2012-12-19 HU HUE12859920A patent/HUE045656T2/en unknown
- 2012-12-19 EP EP12859920.6A patent/EP2794654B1/en active Active
- 2012-12-19 PT PT12859920T patent/PT2794654T/en unknown
- 2012-12-19 JP JP2014548811A patent/JP6306513B2/en active Active
- 2012-12-19 UA UAA201408042A patent/UA114902C2/en unknown
- 2012-12-19 AU AU2012359039A patent/AU2012359039B2/en active Active
- 2012-12-19 CA CA3234629A patent/CA3234629A1/en active Pending
- 2012-12-19 PL PL12859920T patent/PL2794654T3/en unknown
- 2012-12-19 DK DK12859920.6T patent/DK2794654T3/en active
- 2012-12-19 SI SI201231610T patent/SI2794654T1/en unknown
- 2012-12-19 SG SG11201403106SA patent/SG11201403106SA/en unknown
- 2012-12-19 EP EP19173615.6A patent/EP3578567A1/en active Pending
- 2012-12-19 TR TR2019/10720T patent/TR201910720T4/en unknown
- 2012-12-19 CA CA2859665A patent/CA2859665C/en active Active
- 2012-12-19 RS RS20190932A patent/RS59024B1/en unknown
-
2014
- 2014-06-10 IL IL233051A patent/IL233051B/en active IP Right Grant
- 2014-06-19 NI NI201400061A patent/NI201400061A/en unknown
- 2014-06-20 EC ECIEPI20145975A patent/ECSP14005975A/en unknown
- 2014-06-20 GT GT201400127A patent/GT201400127A/en unknown
- 2014-06-20 PH PH12014501427A patent/PH12014501427B1/en unknown
- 2014-06-20 CO CO14134449A patent/CO6980627A2/en unknown
- 2014-07-18 ZA ZA2014/05317A patent/ZA201405317B/en unknown
-
2015
- 2015-04-24 HK HK15103967.6A patent/HK1203520A1/en unknown
-
2016
- 2016-04-26 US US15/138,635 patent/US9745371B2/en active Active
-
2017
- 2017-07-11 US US15/646,865 patent/US10000559B2/en active Active
- 2017-11-20 AU AU2017264975A patent/AU2017264975B2/en active Active
- 2017-12-21 JP JP2017245019A patent/JP6695317B2/en active Active
-
2018
- 2018-03-07 HK HK18103213.5A patent/HK1244490A1/en unknown
- 2018-05-21 US US15/984,772 patent/US10196440B2/en active Active
- 2018-11-14 IL IL263021A patent/IL263021B/en active IP Right Grant
-
2019
- 2019-06-10 JP JP2019108147A patent/JP6987809B2/en active Active
- 2019-07-25 HR HRP20191342 patent/HRP20191342T1/en unknown
- 2019-08-06 CY CY20191100834T patent/CY1121862T1/en unknown
-
2020
- 2020-02-10 JP JP2020020482A patent/JP6987904B2/en active Active
-
2021
- 2021-03-03 IL IL281250A patent/IL281250A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
SG11201408124PA (en) | Differentiation of human embryonic stem cells into pancreatic endocrine cells | |
SG11201907754RA (en) | Anti-phf-tau antibodies and uses thereof | |
SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201808693WA (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
SG11201407028WA (en) | St2l antagonists and methods of use | |
SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
SG11201408261UA (en) | Syringe | |
SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
SG11201406963RA (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
SG11201407505XA (en) | Aptamer-based multiplexed assays | |
SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production | |
SG11201408228QA (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof |